The role of mitochondria in the resistance of melanoma to PD-1 inhibitors

Table 1 The current status of immunotherapy for melanoma

Therapeutic method	Reagent	Mechanism	References
CTLA-4inhibitor	Ipilimumab	Anti-CTLA4 antibody	[24, 25]
CTLA-4inhibitor	Tremelimumab	Anti-CTLA4 antibody	[26]
PD-1 inhibitor	Nivolumab	Anti-PD-1 antibody	[27]
	Pembrolizumab	Anti-PD-1 antibody	[15, 28]
	Cemiplimab	Anti-PD-1 antibody	[29]
PD-L1 inhibitor	Atezolizumab	Anti- PD-L antibody	[30, 31]
	Avelumab	Anti- PD-L antibody	[32]
	Durvalumab	Anti- PD-L antibody	[33]
Others	Interferon-alfa2b and pegylated-interferon-alpha2b	Cytokine activation of T-Cells	[34, 35]
	Talimogene laherparepvec(T-VEC)	Oncolytic virus	[36]
	Relatlimab	Anti- LAG-3 antibody	[37]

ISSN: 1479-5876